The FDA panel just overruled its own scientists on peptides
The short version: an FDA advisory committee has recommended that six of the most widely used peptides, including BPC-157, move toward legal, physician-supervised compounding. It is the first real sign of a legitimate pathway opening up after years of a chaotic gray market. Here is what it means and why it matters.
